All In Biotech

NDA 219921 · Avyxa Holdings

Kyxata

Carboplatin · Intravenous · Platinum-based Drug

Last checked: Nov 20, 2026Latest source record: Aug 8, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Aug 8, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4,077

917 Phase 3, 732 recruiting

FAERS reports

130,077

124,012 serious, 20,461 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS Serious and life-threatening hypersensitivity reactions, including anaphylaxis, can occur with KYXATA within minutes of administration during any cycle. Immediately discontinue KYXATA for severe hypersensitivity reactions and administer appropriate treatment for management of the hypersensitivity reaction [see Warnings and Precautions (5.1) ]. WARNING: HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS Serious and life-threatening hypersensitivity reactions, including anaphylaxis, can occur with KYXATA within minutes of administration during any cycle. ( 5.1 ) Immediately withhold KYXATA for severe hypersensitivity reactions and administer appropriate treatment for management of the hypersensitivity reaction. ( 5.1 )

What it is approved for

From the label in effect Nov 9, 2026.

KYXATA is a platinum-based drug indicated in adults: As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma. ( 1.1 ) As a single-agent for the treatment of ovarian carcinoma recurrent after prior chemotherapy. ( 1.2 ) 1.1 Initial Treatment of Advanced Ovarian Carcinoma KYXATA, as part of a combination regimen, is indicated for the initial treatment of adults with advanced ovarian carcinoma. 1.2 Recurrent Advanced Ovarian Carcinoma KYXATA is indicated for treatment of adults with ovarian carcinoma recurrent after prior chemotherapy.

Mechanism: Carboplatin is a platinum-based drug that binds to DNA and forms DNA cross-links. These crosslinks inhibit DNA replication and transcription and trigger cytotoxic processes that lead to cell death.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 8, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetter
3 products under this application
  • KYXATA · CARBOPLATIN 500MG/50ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • KYXATA · CARBOPLATIN 20MG/2ML (10MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • KYXATA · CARBOPLATIN 80MG/8ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Carboplatin" as an intervention, any sponsor and status, largest first.

All 4,077 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use8,814
  • neutropenia7,633
  • anaemia7,391
  • nausea7,205
  • febrile neutropenia6,742
  • diarrhoea6,425
  • malignant neoplasm progression6,347
  • disease progression6,172
  • thrombocytopenia6,085
  • dyspnoea5,535
  • vomiting5,279
  • pyrexia4,983

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,263
20051,451
20061,358
20071,482
20081,356
20091,645
20101,876
20112,493
20123,407
20132,798
20142,638
20153,759
20164,289
20175,629
20187,631
20197,570
20207,832
20219,234
202211,523
202312,551
202413,571
202514,133
202610,587

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 16, 2026

    Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50).

  • Current · updated Nov 16, 2026

    Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,135 on PubMed

Sponsor: Avyxa Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.